Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 1.00 |
| ▸ | ATRIP | Q8WXE1 | 20/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.74 |
| ▸ | MTOR | P42345 | 1/20 | 0.74 |
| ▸ | PRKDC | P78527 | 1/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20081864 | 1.00 | ATR (1.00) | ATRATRIPGAKCYP3A4CYP2C8 | |
| SCHEMBL17501562 | 0.89 | ATR (1.00) | ATRATRIPGAKCYP3A4CYP2C8 | |
| SCHEMBL20081934 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL17527303 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL29397715 | 0.88 | ATR (1.00) | ATRATRIP | |
| SCHEMBL18121328 | 0.87 | ATR (0.79) | ATRATRIP | |
| SCHEMBL17501354 | 0.87 | ATR (1.00) | ATRATRIPGAKCYP3A4CYP2C8 | |
| SCHEMBL20081859 | 0.86 | ATR (1.00) | ATRATRIP | |
| SCHEMBL17501313 | 0.86 | ATR (1.00) | ATRATRIP | |
| SCHEMBL17501220 | 0.86 | ATR (1.00) | ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660301-B2 | Combination of ATR kinase inhibitors with PARP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-05-30 | — | — | US | claimed |
| US-20210128572-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-05-06 | — | — | US | claimed |
| US-20210128723-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-05-06 | — | — | US | claimed |
| EP-3177619-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2018-04-25 | — | — | EP | claimed |
| US-20170216304-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | claimed |
| EP-3177619-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-14 | — | — | EP | claimed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | claimed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | claimed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | claimed |
| US-20230346927-A1 | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-02 | — | — | US | disclosed |
| US-11690911-B2 | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11660301-B2 | Combination of ATR kinase inhibitors with PARP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-05-30 | — | — | US | disclosed |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
| US-20150125390-A1 | 18F-LABELLED FOLATE/ANTIFOLATE ANALOGUES | Merck & Cie (CH) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150125390-A1 | 18F-LABELLED FOLATE/ANTIFOLATE ANALOGUES | FOLR1, FOLR2, SLC19A1 | ATR 4286/4885ATRIP 2337/4885GAK 2550/4885 |
| US-11690911-B2 | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors | ATR, PDCD1, CHEK1 | ATR 1/4885ATRIP 7/4885GAK 174/4885 |
| US-20210128572-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS | ATR, CHEK1, PARP1 | ATR 1/4885ATRIP 6/4885GAK 66/4885 |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | ATR 3508/4885ATRIP 1927/4885GAK 620/4885 |
| US-20210128723-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | ATR, PDCD1, CHEK1 | ATR 1/4885ATRIP 7/4885GAK 156/4885 |
| US-20170216304-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ATR 3508/4885ATRIP 1927/4885GAK 620/4885 |
| US-20230346927-A1 | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | ATR, PDCD1, CHEK1 | ATR 1/4885ATRIP 7/4885GAK 165/4885 |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ATR 3508/4885ATRIP 1927/4885GAK 620/4885 |
| US-11660301-B2 | Combination of ATR kinase inhibitors with PARP inhibitors | ATR, CHEK1, PARP1 | ATR 1/4885ATRIP 6/4885GAK 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.